Trial · NCT02259582
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
NCT02259582, Phase 2, Completed, OncoMed Pharmaceuticals, Inc.; results first posted 2018-08-20
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer. Trials, record NCT02259582. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02259582
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
- NCT number
- NCT02259582
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 82 participants, actual
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Conditions
- Nonsquamous Nonsmall Cell Neoplasm of Lung
- Interventions
- Pemetrexed, Carboplatin, demcizumab
- First posted
- 2014-10-08
- Last updated
- 2020-09-09
- Results first posted
- 2018-08-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Response assessment data was collected until the subject started alternative anti-cancer treatment or developed progressive disease, whichever occurred first, assessed up to approximately 26 months. | Investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 response rate (unconfirmed) in placebo/placebo arm to demcizumab/placebo arm and demcizumab/demcizumab arm combined in subjects with first-line stage IV non-small cell lung cancer (NSCLC). Response rate was based on Investigator-assessed best-overall-response (BOR) and was defined as the best unconfirmed response determined by RECIST version 1.1 recorded from the start of the treatment until disease progression in the following order of importance: CR, PR , SD, progressive disease (PD), not evaluable, or missing. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Response assessment data was collected until the subject started alternative anti-cancer treatment or developed progressive disease, whichever occurred first, assessed up to approximately 26 months. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Complete response (CR) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Complete response (CR) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Complete response (CR) | 0 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Partial response (PR) | 13 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Partial response (PR) | 10 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Partial response (PR) | 6 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Stable disease (SD) | 10 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Placebo Arm (Arm 2) | Stable disease (SD) | 14 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Demcizumab/Demcizumab Arm (Arm 3) | Stable disease (SD) | 15 | Participants | |
| To Compare the Investigator-assessed (RECIST) v1.1 Response Rate in the Treatment Arms. | Placebo/Placebo Arm (Arm 1) | Progressive disease (PD) | 2 | Participants |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo/Placebo Arm (Arm 1) | 25 | |
| Overall Study | STARTED | Demcizumab/Placebo Arm (Arm 2) | 28 | |
| Overall Study | STARTED | Demcizumab/Demcizumab Arm (Arm 3) | 29 | |
| Overall Study | COMPLETED | Placebo/Placebo Arm (Arm 1) | 9 | |
| Overall Study | COMPLETED | Demcizumab/Placebo Arm (Arm 2) | 11 | |
| Overall Study | COMPLETED | Demcizumab/Demcizumab Arm (Arm 3) | 8 | |
| Overall Study | NOT COMPLETED | Placebo/Placebo Arm (Arm 1) | 16 | |
| Overall Study | NOT COMPLETED | Demcizumab/Placebo Arm (Arm 2) | 17 | |
| Overall Study | NOT COMPLETED | Demcizumab/Demcizumab Arm (Arm 3) | 21 |
Source ClinicalTrials.gov
Adverse events300
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Placebo/Placebo Arm (Arm 1) | 4 | 25 | 4 |
| other | Hypertension | Vascular disorders | Demcizumab/Placebo Arm (Arm 2) | 14 | 28 | 14 |
| other | Hypertension | Vascular disorders | Demcizumab/Demcizumab Arm (Arm 3) | 12 | 29 | 12 |
| other | Hypotension | Vascular disorders | Placebo/Placebo Arm (Arm 1) | 4 | 25 | 4 |
| other | Hypotension | Vascular disorders | Demcizumab/Placebo Arm (Arm 2) | 2 | 28 | 2 |
| other | Hypotension | Vascular disorders | Demcizumab/Demcizumab Arm (Arm 3) | 3 | 29 | 3 |
| other | Fatigue | General disorders | Placebo/Placebo Arm (Arm 1) | 15 | 25 | 15 |
| other | Fatigue | General disorders | Demcizumab/Placebo Arm (Arm 2) | 16 | 28 | 16 |
| other | Fatigue | General disorders | Demcizumab/Demcizumab Arm (Arm 3) | 12 | 29 | 12 |
| other | Asthenia | General disorders | Placebo/Placebo Arm (Arm 1) | 8 | 25 | 8 |
1 to 10 of 300Source ClinicalTrials.gov
See all 300 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo/Placebo Arm (Arm 1) | 1 | 25 |
| Total, all-cause mortality | Demcizumab/Placebo Arm (Arm 2) | 2 | 28 |
| Total, all-cause mortality | Demcizumab/Demcizumab Arm (Arm 3) | 2 | 29 |
| Total, other adverse events | Placebo/Placebo Arm (Arm 1) | 25 | 25 |
| Total, other adverse events | Demcizumab/Placebo Arm (Arm 2) | 28 | 28 |
| Total, other adverse events | Demcizumab/Demcizumab Arm (Arm 3) | 29 | 29 |
| Total, serious adverse events | Placebo/Placebo Arm (Arm 1) | 6 | 25 |
| Total, serious adverse events | Demcizumab/Placebo Arm (Arm 2) | 11 | 28 |
| Total, serious adverse events | Demcizumab/Demcizumab Arm (Arm 3) | 15 | 29 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02259582
GET https://conductscience.org/api/trials/v1/NCT02259582/events?page=2